Natera Inc (NASDAQ:NTRA)’s share price dropped 6.3% on Monday . The company traded as low as $25.81 and last traded at $25.95, approximately 625,644 shares were traded during mid-day trading. A decline of 6% from the average daily volume of 668,946 shares. The stock had previously closed at $27.69.
NTRA has been the topic of a number of recent research reports. Canaccord Genuity raised their price objective on shares of Natera from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, June 25th. Zacks Investment Research lowered shares of Natera from a “hold” rating to a “sell” rating in a research note on Wednesday, July 17th. Piper Jaffray Companies raised their price objective on shares of Natera from $23.00 to $28.00 and gave the company an “overweight” rating in a research note on Monday, June 10th. Finally, BidaskClub raised shares of Natera from a “sell” rating to a “hold” rating in a research note on Wednesday, June 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $30.14.
The company has a quick ratio of 1.73, a current ratio of 1.85 and a debt-to-equity ratio of 20.88. The company’s 50-day moving average price is $26.35. The stock has a market capitalization of $1.88 billion, a P/E ratio of -12.07 and a beta of 1.51.
In other Natera news, Chairman Matthew Rabinowitz sold 1,418 shares of Natera stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $24.79, for a total value of $35,152.22. Following the sale, the chairman now owns 1,286,612 shares of the company’s stock, valued at $31,895,111.48. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Jonathan Sheena sold 1,033 shares of Natera stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $24.79, for a total transaction of $25,608.07. Following the completion of the sale, the insider now directly owns 240,061 shares in the company, valued at approximately $5,951,112.19. The disclosure for this sale can be found here. Insiders have sold 5,311 shares of company stock worth $132,287 over the last three months. 9.29% of the stock is owned by insiders.
A number of hedge funds have recently made changes to their positions in NTRA. Great West Life Assurance Co. Can raised its position in Natera by 136.8% in the fourth quarter. Great West Life Assurance Co. Can now owns 5,920 shares of the medical research company’s stock worth $80,000 after acquiring an additional 3,420 shares during the period. Legal & General Group Plc raised its position in Natera by 14.5% in the fourth quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock worth $81,000 after acquiring an additional 736 shares during the period. Focused Wealth Management Inc bought a new stake in Natera in the second quarter worth about $83,000. BNP Paribas Arbitrage SA raised its position in Natera by 827.1% in the first quarter. BNP Paribas Arbitrage SA now owns 7,899 shares of the medical research company’s stock worth $163,000 after acquiring an additional 7,047 shares during the period. Finally, Metropolitan Life Insurance Co. NY raised its position in Natera by 431.9% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 11,867 shares of the medical research company’s stock worth $166,000 after acquiring an additional 9,636 shares during the period. 80.12% of the stock is currently owned by institutional investors and hedge funds.
About Natera (NASDAQ:NTRA)
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.